Clinical trials: Malignant Peritoneal Effusion
Liver Cirrhoses, Malignant Ascites
International Alfapump Cohort Study
This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.
- Trial name
- TOPMOST (NCT04326946)
- Testing
- Alfapump
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 400 people
- Sponsor
- Sequana Medical N.V.
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Malignant Ascites, Cancer
A Study of M701 (EpCAM and CD3) in Malignant Ascites
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
- Trial name
- NCT04501744
- Testing
- Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Cancer, Neoplasms
CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
This is a randomized phase IIIb study investigating the treatment of malignant ascites due to epithelial cancer (carcinomas) with the trifunctional antibody catumaxomab.
- Conditions
- Cancer, Neoplasms, Carcinoma, Malignant Ascites
- Trial name
- CASIMAS (NCT00822809)
- Testing
- Catumaxomab, Prednisolone
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 230 people
- Sponsor
- Neovii Biotech
Malignant Ascites
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody
A Randomized, Controlled, Multi-Center Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody (M701) for Intraperitoneal Injection to…
- Trial name
- NCT06432296
- Testing
- M701, paracentesis
- Where
- 2 sites in China
- Volunteers
- 312 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company